Table 1.

IC50 of various antilymphoma medications for MBL2 and HUT78 cell line

DrugClassIC50 MBL2, µMIC50 HUT78, µM
Talazoparib PARP-1 inhibitor 316.8 190 
Bexarotene Rexinoid 45.7 16.9 
Vorinostat HDACi 9.7 0.13 
Romidepsin HDACi 0.0548 0.027 
Methotrexate Folate inhibitor 314.7 38.5 
Pralatrexate Folate inhibitor 115.9 94.5 
Boretzomib Proteosome inhibitor 0.009 0.009 
DrugClassIC50 MBL2, µMIC50 HUT78, µM
Talazoparib PARP-1 inhibitor 316.8 190 
Bexarotene Rexinoid 45.7 16.9 
Vorinostat HDACi 9.7 0.13 
Romidepsin HDACi 0.0548 0.027 
Methotrexate Folate inhibitor 314.7 38.5 
Pralatrexate Folate inhibitor 115.9 94.5 
Boretzomib Proteosome inhibitor 0.009 0.009